GMT Science

What GMT Science does

GMT Science is a French biotechnology company founded in 2020 and headquartered in Rouen, with a second office in Paris. It develops a CE-marked in vitro diagnostic medical device — the GMT Science Microbiome Analysis Software — that delivers clinical-grade gut microbiome analysis to physicians through medical laboratories and hospitals. The product combines high-quality quantitative metagenomics with proprietary AI-based algorithms and standardized analytical procedures to produce reproducible microbiome assessments intended for disease prevention, monitoring, and prognosis, with an initial focus on immuno-oncology and stated expansion intent into liver, bowel, metabolic, and mental health conditions.

The company's technology stack is built around proprietary algorithms that convert raw metagenomic sequencing data into standardized clinical biomarkers, supported by partnerships with leading French research institutions including INRAE, Metagenopolis, French Gut, CHU Rouen Normandie, and Institut Gustave Roussy. Its scientific advisory and technical team includes specialized bioinformatics, data science, and medical science staff, and the company holds CE-mark certification under the EU in vitro diagnostic medical devices framework.

GMT Science operates a B2B enterprise sales model, selling or licensing its diagnostic software to medical laboratories and hospitals that then offer the test to physicians and patients. Pricing is not publicly disclosed and is understood to be quote-based and negotiated via healthcare procurement. The company is privately held and founder-led (CEO Etienne Formstecher, PhD; CTO Raynald de Lahondès, PhD; CFO Benjamin Duplan), with support from French public and regional funders including BPI France, Région Normandie, and Région Île-de-France rather than disclosed venture capital rounds. Distribution is anchored by a partnership with Cerba Healthcare, a national medical biology laboratory network, alongside direct hospital engagement.

Name

GMT Science

Legal name

GMT SCIENCE SAS

Website

https://gmt.bio

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

GMT Science is a French biotech that provides CE-marked, AI-driven gut microbiome analysis software to medical laboratories and hospitals for clinical use, initially targeting immuno-oncology and expanding into chronic disease management.

Ownership category

akta.pro rank

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Microbiome analysis testing services: Revenue generated through medical laboratories and hospitals offering GMT Science's CE-marked microbiome analysis software as an in vitro diagnostic service to physicians and patients

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

GMT Science develops and markets a CE-marked in vitro diagnostic medical device software that performs standardized, clinical-grade gut microbiome analysis using high-quality quantitative metagenomics combined with proprietary AI-based algorithms. The software is offered exclusively through medical laboratories and hospitals as a clinical diagnostic service for physicians, with an initial focus on immuno-oncology applications and planned expansion to chronic diseases such as liver, bowel, metabolic, and mental disorders.

Product overview

GMT Science offers a single unified product: its microbiome analysis software, which is a CE-marked medical device for in vitro diagnostic use. The company leverages standardized analytical procedures, high-quality quantitative metagenomics, and proprietary AI-based algorithms to provide robust and reproducible microbiome analysis to clinicians. The software is offered through medical labs and hospitals, with the company's mission being to enable physicians to leverage the microbiome in clinical practice, starting with immuno-oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• GMT Science Microbiome Analysis Software A CE-marked medical device software for in vitro diagnostic use that delivers standardized, clinical-grade gut microbiome analysis through high-quality quantitative metagenomics and proprietary AI-based algorithms. It is offered to clinicians via medical laboratories and hospitals, with an initial focus on immuno-oncology applications and expansion planned into chronic diseases such as liver, bowel, metabolic, and mental disorders.

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered core, major and minor.

• CHU Rouen NormandiecoreStrategic or Co-development PartnerMajor teaching hospital and research institution in Rouen, France. CHU Rouen Normandie collaborates with GMT Science on clinical research and microbiome analysis validation studies.
• Institut Gustave RoussycoreStrategic or Co-development PartnerPremier cancer research and treatment center in France. Strategic partnership focused on immuno-oncology applications of microbiome analysis.
• French GutcoreStrategic or Co-development PartnerNational French gut microbiome research initiative aimed at establishing reference datasets and standards for gut microbiota research in France.
• Metagenopolis (INRAE)coreStrategic or Co-development PartnerResearch unit focused on metagenomics and microbiome science, part of INRAE (Institut national de recherche pour l'agriculture, l'alimentation et l'environnement).
• INRAEcoreStrategic or Co-development PartnerFrench national research institute for agriculture, food, and environment. Provides scientific expertise and research collaboration for microbiome science.
• Cerba HealthcaremajorStrategic or Co-development PartnerLeading medical biology and pathology laboratory network in France. Partnership for diagnostic service development and deployment.
• European Microbiome Institute (EMIH)minorOthersEuropean microbiome industry association. GMT Science is a member organization.
• PharmabioticminorOthersIndustry organization focused on pharmaceutical and health applications of microbiome science. GMT Science is a member.
• Paris Saclay Cancer Cluster (PSCC)minorStrategic or Co-development PartnerCancer research and innovation cluster on the Paris-Saclay campus, supporting collaboration between research institutions and companies.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Enterome: French microbiome-based diagnostics and therapeutics company developing clinical-grade gut microbiome biomarkers for oncology and inflammatory diseases. Highly comparable to GMT Science in geography, technology stack, and target indications.
• CosmosID: US-based microbiome analytics platform providing NGS-based taxonomic and functional profiling with cloud-based AI analysis. Comparable as a clinical/research microbiome analytics provider serving similar lab and biopharma customers.
• Clinical Microbiomics: Denmark-based microbiome analytics and bioinformatics firm offering end-to-end gut microbiome sequencing, metagenomics, and AI-driven analysis to clinical and pharma customers. Comparable in service model and analytical approach.

Broad incumbents

• Diversigen (Eurofins): Microbiome services arm of Eurofins, a large global life-sciences lab network providing sequencing, metagenomics, and bioinformatics services. Overlaps with GMT Science in gut microbiome analytics but operates at far broader scale and across many research customers.
• Viome Life Sciences: Consumer and clinical microbiome testing company using metagenomic sequencing and AI for gut health, oral health, and chronic disease insights. Comparable in combining quantitative metagenomics with proprietary AI interpretation, but targets consumer and DTC channels.

Emerging players

• MaaT Pharma: French microbiome-focused biotech developing microbiome-based therapeutics for oncology and critical care. Shares the French microbiome clinical ecosystem and oncology focus, but operates on the therapeutic rather than diagnostic side.
• DayTwo: Microbiome-based personalized metabolic health platform using gut microbiome profiling and AI for glycemic management. Comparable as a clinical-grade gut microbiome diagnostic service but positioned in chronic disease (diabetes/obesity) rather than oncology.
• ZOE: UK-based personalized nutrition company combining gut microbiome testing with predictive models for metabolic health. Comparable microbiome-as-clinical-input approach with proprietary AI modeling, but B2C positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xbsky.app/profile/gmtscience.bsky.social
• LinkedInlinkedin.com/company/gmt-science

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GMT Science